GLP-1s: What They Are and How They Work
US$ 29.77
glp-1 obesity drug news updates How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Use of diabetes and anti-obesity
Description
In late April 2025, the FDA issued a key update regarding the use of compounded GLP-1 receptor agonists like semaglutide and tirzepatide
Suggested Use
GLP-1 2.0: where will the next wave of value come from
Explore GLP-1 medications like Ozempic and Wegovy
By including all English-language studies on muscle mass loss during GLP-1RA therapy in T2D and obesity from major scientific databases and clinical trial registries, this narrative review synthesizes the current knowledge on the epidemiology and mechanisms of muscle loss in diabetes and obesity, with a focus on the impact of GLP-1RAs therapy
